Syverson Strege & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Syverson Strege & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	393
2021 Q3	$0	Buy	+1	New	+$151	﹤0.01%	459

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Syverson Strege & Co's JAZZ Position: Q4 2021 in Review

Syverson Strege & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 1 share.

Syverson Strege & Co first reported a position in JAZZ in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

Syverson Strege & Co reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Syverson Strege & Co sold 1 Jazz Pharmaceuticals share in Q4 2021.
Syverson Strege & Co first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Syverson Strege & Co's Jazz Pharmaceuticals position peaked at $0 in Q3 2021.
454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Syverson Strege & Co's 13F filing for Q4 2021, filed 19 Jan 2022.